Amgen Inc

AMGN

Healthcare|Drug Manufacturers - General|USA

$342.57

-5.37 (-1.54%)

DCF (FCF)

$219.78

Earnings Power

$83.10

About

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Stock Price

+10.6%(1Y)

Pipeline Summary

540 total trials

142

Phase 1

183

Phase 2

134

Phase 3

Phase 4

Completed: 358Unknown: 17Withdrawn: 18Recruiting: 37Terminated: 72NOT_YET_RECRUITING: 5Active: 29AVAILABLE: 1ENROLLING_BY_INVITATION: 1SUSPENDED: 1APPROVED_FOR_MARKETING: 1

Active Trials (66)

TIDHI Mental Health in IBD Patients Study

NCT07013578Crohn Disease (CD)

N/ARecruiting

Enrollment: 100 participants

PsoBest - The German Psoriasis Registry

NCT01848028Psoriasis

Recruiting

Enrollment: 3,500 participants

German Spondyloarthritis Inception Cohort

NCT01277419Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)

Recruiting

Enrollment: 1,000 participants

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758Extensive Stage Small Cell Lung Cancer

Phase 1Recruiting

Enrollment: 380 participants

Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada

NCT02009345Familial Hypercholesterolemia

Recruiting

Enrollment: 6,000 participants

View all 66 active trials →

BioScore

7.8/10

Buy

Ownership

Recent Insider Trades

Santos EstebanSELL

2026-02-2654,792 shares @ $379.12

Busch Matthew C.SELL

2026-02-191,000 shares @ $375.79

Grygiel Nancy A.SELL

2025-11-203,139 shares @ $337.26

Khosla RachnaSELL

2025-11-12890 shares @ $336.24

Gordon MurdoSELL

2025-11-126,879 shares @ $336.83

Recent News

2026-04-06 17:50:27

2026-04-06 15:25:53

2026-04-06 14:00:08

2026-04-06 13:52:27

2026-04-01 12:29:16

Data last updated: Apr 7, 2026, 03:34 AM